Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 26 Apr 2023
More than 90% of people in the world own or use a mobile phone, and many of us couldn't live without them. We carry them everywhere we go, use them in bed and the bathroom, and for many people, they are the first thing they see in the morning.
Read Full NewsA 36-year-old woman with a 2-year history of hairline recession and eyebrow thinning shows marked regrowth after early multimodal therapy with dutasteride, tofacitinib, and intralesional steroids.
With a mental health care provider shortage and many patients’ seeking mental health support, primary care doctors have stepped up to the front lines.
While tuberculosis spread is not significant nationally, lack of awareness of the latent form of the condition raises legitimate concerns for potential future infections.
The U.S. and the Global Fund to Fight AIDS, Tuberculosis and Malaria are stepping up efforts to broaden access to Gilead's HIV prevention drug, with a goal of reaching 3...
Fewer resources through Gavi, the Vaccine Alliance, may limit vaccine administration at the local level.
Monthly injectable HIV therapy shows lower treatment failure than oral regimens in individuals with adherence challenges.
A subgroup analysis hints that chemotherapy may be skipped after complete resection, but the finding needs further study.
1.
For the treatment of paroxysmal nocturnal hemoglobinuria, the FDA has approved an oral factor B inhibitor.
2.
Scholastic performance is a key concern for young cancer patients, study finds
3.
Quality of Life Similar With Proton Beam Therapy vs IMRT for Prostate Cancer
4.
A Win for Molecularly Guided Therapy for Cancer of Unknown Primary
5.
Mapping lifelong chronic health risks for childhood cancer survivors
1.
Transplant Oncology and Anti-Cancer Immunosuppressants: The Evolution of a Paradigm in Cancer Care
2.
Unlocking the Secrets of Hemoglobin: Exploring the Wonders of Life-Sustaining Iron Compounds
3.
Bridging the Gap Between Cancer Treatment-Induced Cardiotoxicity and Regenerative Medicine
4.
The Science Behind Thrombolytic Drugs and Their Benefits
5.
Alectinib in Resected ALK-Positive Non-Small-Cell Lung Cancer
1.
International Lung Cancer Congress®
2.
Genito-Urinary Oncology Summit 2026
3.
Future NRG Oncology Meeting
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Targeting Oncologic Drivers with Dacomitinib: Further Discussion on Lung Cancer Treatment
2.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia
4.
A New Era in Managing Cancer-Associated Thrombosis
5.
Exploring Potentials of Lorlatinib: The Third Generation ALK-TKI Through CROWN Trial
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge